ArticleOncology letters2013
Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer.
Article in Oncology letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The expression profile and clinic significance of the SIX family in non-small cell lung cancer.Journal of hematology & oncology · 2016Pooled it
- A Novel Prognostic DNA Methylation Panel for Colorectal Cancer.International journal of molecular sciences · 2019Trial
- Review
- Forkhead box L2 is a target of miR-133b and plays an important role in the pathogenesis of non-small cell lung cancer.Cancer medicine · 2023Article
- T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma.Journal of clinical medicine · 2022Article
- Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma.Journal of oncology · 2022Article
- Microarray analysis of genes with differential expression of m6A methylation in lung cancer.Bioscience reports · 2021Article
- Investigation the Role of Autophagy in Non-Small Cell Lung Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Paired-like homeodomain 2B contributes to tumour progression and anti-autophagy in human lung cancer.American journal of cancer research · 2021Article
- The SIX Family of Transcription Factors: Common Themes Integrating Developmental and Cancer Biology.Frontiers in cell and developmental biology · 2021Review
- Health inequality: a longitudinal study on geographic variations in lung cancer incidence and mortality in Taiwan.BMC public health · 2020Article
- Article
- [Application of GLAD-PCR Assay for Study on DNA Methylation in Regulatory Regions of Some Tumor-Suppressor Genes in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.The Journal of investigative dermatology · 2019Article
- Article
- Expression of a SOX1 overlapping transcript in neural differentiation and cancer models.Cellular and molecular life sciences : CMLS · 2017Article
- Refined-mapping of the novel TSG within the 17q24.3 chromosomal region in non-small cell lung cancer samples.Oncology letters · 2016Article
- Role ofOncoTargets and therapy · 2016Article
- Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC).Clinical epigenetics · 2015Article
- Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma.BMC systems biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP). The methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P<0.05). The co-methylation of SIX6 and SOX1, or the co-methyaltion of SIX6, RARB and SOX1 was associated with adenosquamous carcinoma (ADC), and the co-methylation of BCL2, RARB and SIX6 was associated with smoking. A panel of 4 genes (MYF6, SIX6, BCL2 and RARB) may offer a sensitivity of 93.07% and a specificity of 83.33% in the diagnosis of stage I NSCLC. Furthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively. In this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC. Further study of these genes shed light on the carcinogenesis of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.